BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Equity Ratio

The Equity Ratio of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 43.28 %. In the previous year, Equity Ratio was 46.37 % — a change of -6.65% (lower).

Equity Ratio

43.28 %

YoY

-6.65%

Last updated:

Equity Ratio of BrightGene Bio-Medical Technology Co is 2025 43.28 % . Equity Ratio of BrightGene Bio-Medical Technology Co was 2024 46.37 % . It decreases by -6.65% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
87.99 CNY
Jan 1, 2019
92.39 CNY
Jan 1, 2020
78.33 CNY
Jan 1, 2021
56.51 CNY
Jan 1, 2022
47.02 CNY
Jan 1, 2023
47.07 CNY
Jan 1, 2024
46.37 CNY
Jan 1, 2025
43.28 CNY
The BrightGene Bio-Medical Technology Co Equity Ratio history
YEAREquity RatioYoY
43.28 %-6.65%
46.37 %-1.50%
47.07 %+0.12%
47.02 %-16.80%
56.51 %-27.86%
78.33 %-15.21%
92.39 %+5.00%
87.99 %+3.55%
84.97 %+48.29%
57.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Equity Ratio of BrightGene Bio-Medical Technology Co is 43.28 % in 2025.

Equity Ratio of BrightGene Bio-Medical Technology Co changed from 46.37 % to 43.28 %, representing a -6.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co